Nagpur: More than 70 lakh children in Vidarbha in the age group 2-18 years are now eligible to get Jab Covaxin, which received an emergency approval of the use of the Subject Expert Committee (SEC) from the Indian Control Medication (DCGI) on Tuesday.
Nagpur district alone has 11 pediatric populations of Lakh which qualifies for vaccines.
Right from the beginning, Nagpur has played an important role in human trials from Covaxin.
Good for elders or for children, Nagpur has become a constant trial site for a fully made-in-Indian vaccine by Bharat Biotech.
Senior Pediatrician Dr.
Vasant Khalatkar, who is the main researcher for Covaxin pediatric trials, said that the trial held at Nagpur showed amazing results in children.
“This is a pleasant surprise for me that Covaxin has accepted the current emergency use authorization.
In Nagpur, we have tested it in children in the age group 2-18 years.
While the safety of vaccines has been proven, the results of the efficacy also promises,” said Dr.
Khalatkar .
According to him, vaccines for children will play an important role in bringing life to normal.
“Everyone talks about the possibility of the third wave, which is expected to be hit in November and will target children who are the only population segments that are not vaccinated now.
If we launch vaccines for children, we can certainly avoid the third wave, “added Khalatkar.
The Paediatrics (AOP) Academy, President of Nagpur Dr.
Vijay Dhote said that the government must allow pediatric people to procure and manage vaccines.
“People prefer to get Jab given from their family doctor, rather than going to the center.
Even though school is now open, many parents are reluctant to send their wards because they are not vaccinated.
So, we need to launch drive vaccines for the earliest kids , “Dr.
Dhote said.
Apart from Covaxin, Zycov-D, which is the only DNA vaccine, has also received similar approval and can be used to be used to immunize younger populations even before Covaxin.